Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biopharma company Crucell has announced that an agreement was reached to relocate the company's Korean production facility, where its pentavalent children's vaccine Quinvaxem and a hepatitis B vaccine Hepavax-Gene are produced, from the Shingal site in Yongin City, Korea to the Incheon free economic zone.
Subscribe to our email newsletter
All parties involved have agreed on the time line and conditions of this relocation, enabling a smooth transition to the new production facility, the company said.
The new facility will enable the further growth and efficient production of Quinvaxem and Hepavax-Gene.
Cees Jong, COO of Crucell, said: “We are pleased that we were able to settle all litigation around our production facility amicably, on terms beneficiary to all parties. Production of Quinvaxem at our existing site in Shingal has already doubled compared to last year, and the new production facility will support the expected growth of our flagship products in the years to come.”